Trial intelligence / Profile preview

ACCENT I: Infliximab Maintenance in Crohn's Disease

NCT00207662Phase 3Completed

Sponsor
Janssen Pharmaceutical
Start
Jul 2000
Modality
Monoclonal Antibodies
01

Overview

A Phase 3 trial of infliximab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Jul 2000; status: completed.

02

Drugs

infliximab
03

Conditions

Crohn's disease

Beyond the preview

Go deeper on NCT00207662.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00207662.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call